Breaking News Instant updates and real-time market news.

BOLD

Audentes Therapeutics

$24.65

0.36 (1.48%)

09:23
01/11/19
01/11
09:23
01/11/19
09:23

Audentes Therapeutics upgraded to Buy at Guggenheim on positive AT132 outlook

As reported earlier, Guggenheim analyst Whitney Ijem upgraded Audentes Therapeutics to Buy from Neutral with a price target of $35 at the conclusion of the JPMorgan Healthcare conference this week. The analyst says that he is "incrementally more positive" on the company's A132 program after the meeting, anticipating "productive regulatory and data updates in the near term." Ijem further expects 2019 to be a year of of "pipeline progress" for Audentes Therapeutics now that the Pompe program is "back on track" and ahead of more details about a larger neuromuscular indication.

BOLD Audentes Therapeutics
$24.65

0.36 (1.48%)

11/07/18
WBLR
11/07/18
DOWNGRADE
WBLR
Market Perform
Audentes downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Audentes Therapeutics to Market Perform following the company's Q3 results. The analyst says increased competition in Pompe disease is giving him pause.
11/07/18
11/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Underperform from Sector Perform at RBC Capital with analyst Stephen Walker saying he points to the company's premium valuation ahead of what he expects to be a decline in 2019 production. 2. Zillow (Z, ZG) downgraded to Sell from Hold at Zelman and to Negative from Neutral at Susquehanna. 3. Mindbody (MB) downgraded to Neutral from Buy at UBS and Roth Capital as well as to Neutral from Overweight at JPMorgan. 4. Frontier Communications (FTR) downgraded to Sell from Neutral at UBS with analyst Batya Levi saying Frontier's free cash flow remains under pressure. 5. Audentes downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying increased competition in Pompe disease is giving him pause. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/18
JPMS
11/26/18
INITIATION
Target $35
JPMS
Overweight
Audentes Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Audentes Therapeutics with an Overweight rating and $35 price target. The stock has pulled 40% since early October, which represents an attractive long-term entry point, Rama tells investors in a research note. He believes the "de-risked nature" of the known clinical data for gene therapy lead assets AT132 in X-Linked Myotubular Myopathy and AT342 in Crigler-Najjar Syndrome "goes underappreciated" at current share levels.
01/11/19
GUGG
01/11/19
UPGRADE
GUGG
Buy
Audentes Therapeutics upgraded to Buy from Neutral at Guggenheim

TODAY'S FREE FLY STORIES

RDFN

Redfin

$18.49

0.48 (2.67%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Redfin rating change  »

Redfin downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

, TK

Teekay Corp.

$3.74

0.28 (8.09%)

07:46
01/22/19
01/22
07:46
01/22/19
07:46
Downgrade
Teekay Offshore Partners, Teekay Corp. rating change  »

Teekay Offshore Partners…

TOO

Teekay Offshore Partners

$1.42

0.07 (5.19%)

TK

Teekay Corp.

$3.74

0.28 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OZK

Bank OZK

$32.07

4.47 (16.20%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Bank OZK analyst commentary  »

Bank OZK price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$333.74

3.69 (1.12%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

TGTX

TG Therapeutics

$4.51

0.095 (2.15%)

07:45
01/22/19
01/22
07:45
01/22/19
07:45
Hot Stocks
TG Therapeutics announces breakthrough therapy designation for umbralisib »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXP

Lexington Realty

$9.01

0.01 (0.11%)

07:44
01/22/19
01/22
07:44
01/22/19
07:44
Upgrade
Lexington Realty rating change  »

Lexington Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$6.83

-0.19 (-2.71%)

07:43
01/22/19
01/22
07:43
01/22/19
07:43
Hot Stocks
Cytokinetics announces FDA feedback for potential reldesemtiv program »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$22.94

0.99 (4.51%)

, FISV

Fiserv

$77.83

3.23 (4.33%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Downgrade
First Data, Fiserv rating change  »

First Data downgraded to…

FDC

First Data

$22.94

0.99 (4.51%)

FISV

Fiserv

$77.83

3.23 (4.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

SAIC

SAIC

$66.03

0.38 (0.58%)

07:42
01/22/19
01/22
07:42
01/22/19
07:42
Conference/Events
SAIC management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

PSEC

Prospect Capital

$6.74

0.04 (0.60%)

07:41
01/22/19
01/22
07:41
01/22/19
07:41
Downgrade
Prospect Capital rating change  »

Prospect Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOG

GasLog

$18.21

0.7 (4.00%)

07:40
01/22/19
01/22
07:40
01/22/19
07:40
Downgrade
GasLog rating change  »

GasLog downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

OFG

OFG Bancorp

$18.14

0.19 (1.06%)

07:40
01/22/19
01/22
07:40
01/22/19
07:40
Earnings
OFG Bancorp reports Q4 EPS 45c, consensus 42c »

Net income available to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 07

    Feb

  • 27

    Feb

07:40
01/22/19
01/22
07:40
01/22/19
07:40
General news
Treasury Market Outlook: Treasury yields are lower in risk-off trades »

Treasury Market Outlook:…

TPC

Tutor Perini

$18.33

0.5 (2.80%)

07:39
01/22/19
01/22
07:39
01/22/19
07:39
Downgrade
Tutor Perini rating change  »

Tutor Perini downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$5.53

-0.12 (-2.12%)

07:38
01/22/19
01/22
07:38
01/22/19
07:38
Hot Stocks
Translate Bio announces clinical hold on MRT5201 IND application from FDA »

Translate Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSY

Insys Therapeutics

$4.42

-0.25 (-5.35%)

07:37
01/22/19
01/22
07:37
01/22/19
07:37
Initiation
Insys Therapeutics initiated  »

Insys Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCM

R1 RCM

$8.32

0.16 (1.96%)

07:37
01/22/19
01/22
07:37
01/22/19
07:37
Initiation
R1 RCM initiated  »

R1 RCM initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$49.23

0.76 (1.57%)

07:36
01/22/19
01/22
07:36
01/22/19
07:36
Recommendations
Intel analyst commentary  »

Intel Q4 results should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

ONCS

OncoSec

$0.71

0.0134 (1.93%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Conference/Events
OncoSec management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

D

Dominion

$68.75

-0.15 (-0.22%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Downgrade
Dominion rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 10

    Feb

UBSH

Union Bankshares

$32.50

0.14 (0.43%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Earnings
Union Bankshares reports Q4 ex-items EPS 70c, consensus 68c »

Q4 net charge-offs were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 11

    Feb

JD

JD.com

$23.25

1.12 (5.06%)

, INTC

Intel

$49.23

0.76 (1.57%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

JD

JD.com

$23.25

1.12 (5.06%)

INTC

Intel

$49.23

0.76 (1.57%)

WYNN

Wynn Resorts

$115.19

0.94 (0.82%)

NKE

Nike

$80.45

1.33 (1.68%)

CRON

Cronos Group

$14.89

1.25 (9.16%)

MGM

MGM Resorts

$28.55

0.83 (2.99%)

AUY

Yamana Gold

$2.31

-0.12 (-4.94%)

UAA

Under Armour

$20.50

0.47 (2.35%)

I

Intelsat

$21.15

-1.26 (-5.62%)

APC

Anadarko

$48.68

0.61 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 06

    Feb

  • 10

    Feb

  • 13

    Feb

  • 21

    Feb

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

INCY

Incyte

$78.44

-0.22 (-0.28%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Hot Stocks
Incyte treats first patient in Phase 3 clinical trial of itacitinib »

Incyte Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

AMBR

Amber Road

$8.45

0.19 (2.30%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Hot Stocks
Amber Road confirms receipt of director nominations from Altai Capital »

Amber Road confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 11

    Feb

CORV

Correvio

$3.24

0.365 (12.70%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Recommendations
Correvio analyst commentary  »

Correvio to unlock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.